BIOMARIN PHARMACEUTICAL INC
BIOMARIN PHARMACEUTICAL INC (BMRN): 9 pipeline candidates · 6 upcoming catalysts · ~24 mo cash runway · 30 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
24.2 months
D/E 0.38 · 2% dilution
Lead: Phase 2/Phase 3
9 candidates
6 upcoming, next in ~44d
0 buys · 4 sells (180d)
A transparent, data-derived signal for BIOMARIN PHARMACEUTICAL INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$10.8B
Cash
$3.1B
Quarterly Burn
$437.1M
Runway
24.2 mo
Revenue
$766.2M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| bmn 111 | Phase 2 |
| bmn 333 | Phase 2/Phase 3 |
| bmn 349 | Phase 1 |
| bmn 351 | Phase 1/Phase 2 |
| cerliponase alfa | — |
| pegvaliase | Phase 3 |
| rdd to palynziq | Phase 4 |
| valoctocogene roxaparvovec | Phase 1/Phase 2 |
| vosoritide injection [voxzogo] | Phase 2/Phase 3 |
Upcoming Catalysts (6)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
553
Total value held
$10.83B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 19,818,301 | $1.12B |
| vanguard capital management llc | 17,286,328 | $976.5M |
| dodge & cox | 14,561,759 | $822.6M |
| primecap management co/ca/ | 14,194,005 | $801.8M |
| vanguard portfolio management llc | 8,298,475 | $468.8M |
| aqr capital management llc | 7,676,541 | $429.3M |
| state street corp | 7,295,079 | $412.1M |
| viking global investors lp | 7,062,077 | $398.9M |
| citadel advisors llc | 4,697,834 | $265.4M |
| geode capital management, llc | 3,819,441 | $215.8M |
Showing top 10 of 553 institutional holders of BIOMARIN PHARMACEUTICAL INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in BIOMARIN PHARMACEUTICAL INC's pipeline?
BIOMARIN PHARMACEUTICAL INC (BMRN) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BIOMARIN PHARMACEUTICAL INC's lead drug candidate?
BIOMARIN PHARMACEUTICAL INC's most advanced tracked candidate is bmn 111 (Phase 2) for Achondroplasia.
What is BIOMARIN PHARMACEUTICAL INC's next catalyst?
BIOMARIN PHARMACEUTICAL INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy " — expected August 1, 2026.
What is BIOMARIN PHARMACEUTICAL INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BIOMARIN PHARMACEUTICAL INC has approximately 24.2 months of cash runway.
What is BIOMARIN PHARMACEUTICAL INC's market capitalization?
BIOMARIN PHARMACEUTICAL INC's market capitalization is approximately $10.8B.
Get the full picture on BIOMARIN PHARMACEUTICAL INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.